Significance of the Phase III FLAURA Study in EGFR+ NSCLC
September 11th 2017Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the randomized phase III FLAURA study of frontline osimertinib (Tagrisso) in patients with EGFR-mutant non-small cell lung cancer.
Watch
An Update on Avelumab as Monotherapy for Urothelial Carcinoma
September 11th 2017Andrea Apolo, MD, medical oncologist at the National Cancer Institute and chief of the bladder cancer section of the Genitourinary Malignancies Branch, discusses the recent updates presented at the 2017 ESMO Annual Congress regarding avelumab (Bavencio) monotherapy for patients with urothelial carcinoma.
Watch
Avelumab Treatment in Patients With Metastatic Merkel Cell Carcinoma
September 10th 2017Celeste Lebbé, MD, from the Hôpital Saint Louis, in Paris, France, discusses avelumab treatment in chemotherapy-naive patients with distant metastatic Merkel cell carcinoma during the 2017 ESMO Annual Congress.
Watch
Dr. Luke Discusses the Combination of Epacadostat and Pembrolizumab in Melanoma
September 9th 2017Jason J. Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses the combination of epacadostat and pembrolizumab (Keytruda) for the treatment of melanoma during the 2017 ESMO Annual Congress.
Watch
Toxicities Associated With Rucaparib for the Treatment of Ovarian Cancer
September 8th 2017Jonathan Ledermann, MD, professor of medical oncology in the University College London Cancer Institute and director of Cancer Research UK and UCL Cancer Trials Centre, discusses the toxicities associated with rucaparib (Rubraca) for the treatment of ovarian cancer.
Watch
Dr. Bazhenova on Current Treatment Strategies for Patients With Nonsquamous NSCLC
September 1st 2017Lyudmila A. Bazhenova, MD, medical oncologist, professor of medicine, UC San Diego Health, discusses the currently available treatment strategies for patients with non-driver non–small cell lung cancer.
Watch
Dr. Bazhenova on Considering Factors to Treat Non-Driver Patients With NSCLC With Bevacizumab
September 1st 2017Lyudmila A. Bazhenova, MD, medical oncologist, professor of medicine, UC San Diego Health, discusses the factors to take into consideration when treating a patient with non-driver non–small cell lung cancer with bevacizumab (Avastin).
Watch
Dr. Bazhenova on Potential Impact of Immunotherapy in Non-Driver NSCLC
September 1st 2017Lyudmila A. Bazhenova, MD, medical oncologist, professor of medicine, UC San Diego Health, discusses what potential impact immunotherapy agents could have on outcomes for patients with non-driver non–small cell lung cancer.
Watch
Dr. Bazhenova on Remaining Challenges and Future Treatment Landscape of Non-Driver NSCLC
September 1st 2017Lyudmila A. Bazhenova, MD, medical oncologist, professor of medicine, UC San Diego Health, discusses ongoing and remaining challenges in the field of non-driver non–small cell lung cancer, as well as a look toward the future treatment landscape.
Watch
Combining Targeted Therapy With Checkpoint Blockade for the Treatment of Melanoma
August 31st 2017Dirk Schadendorf, MD, professor, director, and chair of the clinic for dermatology at the University Hospital Essen in Germany, discusses the combination of targeted therapy and checkpoint blockade for the treatment of melanoma.
Watch
Exploring the Efficacy of Pembrolizumab in Sarcoma Subtypes
August 31st 2017Lisa H. Butterfield, PhD, professor of medicine, surgery, and immunology, director, University of Pittsburgh Immunologic Monitoring and Cellular Products Laboratory, and president of the Society for Immunotherapy of Cancer, discusses the SARC028 study, which explored the efficacy of pembrolizumab (Keytruda) in advanced soft tissue and bone sarcomas.
Watch
The Need for Novel Therapies in Mantle Cell Lymphoma
August 29th 2017Rekha Rao, PhD, assistant professor, University of Kansas Medical Center, discusses the need to develop novel therapies in mantle cell lymphoma, including a study that explored the synergistic activity of p97 inhibitors with histone deacetylase 6 inhibitors.
Watch